Clearance Summary
Ceruloplasmin received FDA 510(k) clearance under submission number K161508, sponsored by Beckman Coulter Ireland, Inc.. The device was reviewed via the Traditional premarket notification pathway and assigned to the Immunology review panel. The statutory decision date of record is 2017-01-09.
- Submission: K161508
- Applicant / Sponsor: Beckman Coulter Ireland, Inc.
- Clearance pathway: Traditional
- Review panel: Immunology
- Device class: Class II
- Regulation citation: 21 CFR 866.5210
- Decision date: 2017-01-09
Classification & Regulation
This clearance is catalogued under FDA product code DDB and 21 CFR 866.5210, within the Immunology review panel as a Class II device.